Innovating Acute Leukaemia Care: Exploring Home-Based Models of Treatment

Innovating Acute Leukaemia Care: Exploring Home-Based Models of Treatment

WCMICS is supporting an innovative pilot project at the Royal Melbourne Hospital to explore safer, more person-centred care models for patients with acute myeloid leukaemia (AML) receiving Venetoclax and Azacitidine (VEN-AZA) therapy. The project focuses on improving treatment delivery for patients who are not eligible for intensive chemotherapy by developing a home-based care model supported by evidence and clinical safeguards.

These changes are expected to reduce hospital stays, improve quality of life, and preserve inpatient resources—without compromising safety. Initial projections suggest that around 30% of patients could benefit from outpatient care during induction, potentially saving 576 bed days per year.

This work represents a bold step toward modernising cancer care delivery by blending clinical innovation with real-world feasibility. If successful, this model could be adapted to other haematology settings across the state.